Literature DB >> 15830143

Validation of the Functional Assessment of Cancer Therapy-Breast Symptom Index (FBSI).

Kathleen J Yost1, Susan E Yount, David T Eton, Cheryl Silberman, Anne Broughton-Heyes, David Cella.   

Abstract

We assessed the reliability, validity, and responsiveness to change of the 6-item Functional Assessment of Cancer Therapy-Breast Symptom Index (FBSI) in a sample of 615 metastatic breast cancer patients. The FBSI is a brief, clinically relevant, and psychometrically sound instrument that can be used to measure symptoms in patients with breast cancer.

Entities:  

Mesh：

Year:  2005        PMID： 15830143     DOI： 10.1007/s10549-004-5024-3

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN： 0167-6806            Impact factor:   4.872


  5 in total

1.  RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer.

Authors:  José Baselga; Claudio Zamagni; Patricia Gómez; Begoña Bermejo; Shigenori E Nagai; Bohuslav Melichar; Arlene Chan; Lászlo Mángel; Jonas Bergh; Frederico Costa; Henry L Gómez; William J Gradishar; Clifford A Hudis; Bernardo L Rapoport; Henri Roché; Patricia Maeda; Liping Huang; Gerold Meinhardt; Joshua Zhang; Lee S Schwartzberg
Journal:  Clin Breast Cancer       Date:  2017-05-22       Impact factor: 3.225

2.  Sequelae of breast cancer and the influence of menopausal status at diagnosis among rural breast cancer survivors.

Authors:  Christie A Befort; Jennifer Klemp
Journal:  J Womens Health (Larchmt)       Date:  2011-06-28       Impact factor: 2.681

3.  The validity and utility of the M. D. Anderson Symptom Inventory in patients with breast cancer: evidence from the symptom outcomes and practice patterns data from the eastern cooperative oncology group.

Authors:  Tito R Mendoza; Fengmin Zhao; Charles S Cleeland; Lynne I Wagner; Linda J Patrick-Miller; Michael J Fisch
Journal:  Clin Breast Cancer       Date:  2013-06-28       Impact factor: 3.225

Review 4.  Quality of life assessment in women with breast cancer: benefits, acceptability and utilization.

Authors:  Sheila Perry; Theresa L Kowalski; Chih-Hung Chang
Journal:  Health Qual Life Outcomes       Date:  2007-05-02       Impact factor: 3.186

5.  A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial.

Authors:  José Baselga; Frederico Costa; Henry Gomez; Clifford A Hudis; Bernardo Rapoport; Henri Roche; Lee S Schwartzberg; Oana Petrenciuc; Minghua Shan; William J Gradishar
Journal:  Trials       Date:  2013-07-22       Impact factor: 2.279
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.